In patients with coronary artery disease and peripheral arterial disease, the FXa-inhibitor rivaroxaban reduced atherothrombotic events as shown in the ATLAS ACS 2-TIMI 51 and COMPASS trials [64]. This evidence concerns the gene F10 and peripheral arterial disease.